ImmuCell - Public Comps and Valuation Multiples

ImmuCell Overview

About ImmuCell

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Founded

1982

HQ

Employees

Website

immucell.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
Agriculture
AgriTech
BioTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$60.7M

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

ImmuCell Financials

ImmuCell has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, ImmuCell achieved revenue of $26.5M and an EBITDA of $1.1M.

ImmuCell expects next 12-month revenue of XXX and NTM EBITDA of XXX

See ImmuCell valuation multiples based on analyst estimates

ImmuCell P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$17.5M	$26.5M	XXX	XXX	XXX
Gross Profit	$7.6M	$3.9M	XXX	XXX	XXX
Gross Margin	44%	15%	XXX	XXX	XXX
EBITDA	-$2.6M	$1.1M	XXX	XXX	XXX
EBITDA Margin	-15%	4%	XXX	XXX	XXX
Net Profit	-$2.5M	-$5.8M	XXX	XXX	XXX
Net Margin	-14%	-22%	XXX	XXX	XXX
Net Debt	$4.4M	$11.0M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

ImmuCell Stock Performance

As of April 15, 2025, ImmuCell's stock price is $5.

ImmuCell has current market cap of $49.4M, and EV of $60.7M.

See ImmuCell trading valuation data

ImmuCell Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$60.7M	$49.4M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

ImmuCell Valuation Multiples

As of April 15, 2025, ImmuCell has market cap of $49.4M and EV of $60.7M.

ImmuCell's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate ImmuCell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for ImmuCell and 10K+ public comps

ImmuCell Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$60.7M	XXX	XXX	XXX
EV/Revenue	2.3x	XXX	XXX	XXX
EV/EBITDA	56.9x	XXX	XXX	XXX
P/E	-22.9x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	-563.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ImmuCell Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

ImmuCell Valuation Multiples

ImmuCell's NTM/LTM revenue growth is n/a

ImmuCell's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, ImmuCell's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate ImmuCell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for ImmuCell and other 10K+ public comps

ImmuCell Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	52%	XXX	XXX	XXX	XXX
EBITDA Margin	4%	XXX	XXX	XXX	XXX
EBITDA Growth	-141%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	$0.4M	XXX	XXX	XXX	XXX
Opex per Employee	$0.1M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	13%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	8%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	15%	XXX	XXX	XXX	XXX
Opex to Revenue	36%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry